Canopy Genomics
BiotechSeries CRisk Assessment
Canopy Genomics is operating within normal parameters. Modest 9% headcount decline is within acceptable range for a post-Series C company. Two open roles suggest continued hiring. CEO approval data unavailable — confidence adjusted to Medium.
Signal Dimensions
Competitor Raises
2
SoV Trend
Stable
Talent Outflow
Low
Sector Growth
10%
Genomics sector active. Competitive position stable.
Peak HC
167
Current HC
152
HC Decline
-9%
Open Roles
2
Small headcount decline with active hiring. Normal post-funding optimisation.
GD Rating
4.1
CEO Approval
—
Business Outlook
64%
Review Trend
Stable
Good Glassdoor rating. CEO approval data unavailable but outlook positive.
Last Filing
Feb 2026
Auditor Changes
0
Director Changes
1
Overdue Filings
0
Filings current. One director appointment — normal board expansion.
Last Raise
Series C
Time Since Raise
9 months
Funding Stage
Growth
Burn Indicator
Low
Well-funded post-Series C. No burn concerns.
Articles (12mo)
7
Avg Tone
+0.8
Days w/ Coverage
5
Sentiment
Positive
Positive media presence. Genomics sector attracting favourable coverage.
Score Drivers
No risk drivers detected. All signals within healthy parameters.
Confidence: MED · 5 of 6 signals active
Recommended Actions
Routine monitoring recommended. No escalation required.